ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378
Ru
En

The Role of Kisspeptin in Menstrual Disorders in Adolescent Girls. Treatment of Clinically Manifested Endocrine Abnormalities

DOI:10.31550/1727-2378-2020-19-2-13-19
Bibliography link: Bolotova N.V., Timofeeva S.V., Polyakov V.K., Averiyanov A.P., Popykhova E.B., Korshunovich V.A. The Role of Kisspeptin in Menstrual Disorders in Adolescent Girls. Treatment of Clinically Manifested Endocrine Abnormalities. Doctor.Ru. 2020; 19(2): 13–19. (in Russian) DOI: 10.31550/1727-2378-2020-19-2-13-19
The Role of Kisspeptin in Menstrual Disorders in Adolescent Girls. Treatment of Clinically Manifested Endocrine Abnormalities
22 April 07:56

Objective of the Study: To assess kisspeptin levels in girls of various body weights who have menstrual disorders, and evaluate the efficacy of device-assisted treatment options for patients with clinically manifested endocrine abnormalities.

Study Design: This was a cohort prospective study.

Materials and Methods: Seventy adolescent girls, aged 15 to 17, with various menstrual disorders were examined. They were divided into three groups by body weight. Group 1 consisted of 15 girls with low body weight due to anorexia nervosa; Group 2 was made up of 35 girls with obesity; and Group 3 comprised 20 normal-weight or overweight girls with incipient polycystic ovary syndrome. The control group consisted of 20 healthy girls of the same age.

The examination included an assessment of the girls’ physical development, age of menarche, and menstrual cycle characteristics. The following parameters were measured: kisspeptin, luteinizing hormone (LH), follicle-stimulating hormone, thyroid-stimulating hormone, and sex hormones. The girls also underwent pelvic ultrasound.

Study Results: In girls with protein and calorie deficiency, amenorrhea was the most frequent menstrual disorder. The kisspeptinergic system was suppressed in these girls, which was manifested by significantly low levels of kisspeptin, gonadotropic hormones, and sex hormones. The obese girls had signs of hypercorticism, low levels of kisspeptin, LH, estradiol, and progesterone, and various menstrual disorders. The girls in Group 3 had significantly elevated levels of kisspeptin, total testosterone, and LH, which suggests the contribution of central mechanisms to the development of polycystic ovary syndrome. In Groups 2 and 3, a 10-15-day course of transcranial magnetic stimulation in combination with transcranial electrostimulation normalized the patients’ hormonal status, improved their clinical condition, and restored normal menstrual cycles.

Conclusion: This study revealed an association between kisspeptin levels and physical development parameters in adolescent girls. Significantly low body weight and obesity contribute to suppression of the kisspeptin pathways in the reproductive system, which is associated with various menstrual disorders. High levels of kisspeptin most likely reflect its role in the development of polycystic ovary syndrome. Transcranial stimulation improves patients’ clinical condition and restores a normal menstrual cycle through its regulatory influence on the kisspeptinergic system.

Contribution: Bolotova, N.V. — the concept and design of the study, data analysis, summarizing the study results, and writе the final manuscript; Timofeeva, S.V. — data collection and analysis of the results, as well as taking part in writing the final manuscript; Polyakov, V.K. — data collection and statistical analysis of the study results; Averiyanov, A.P. — assistance with data collection and revision of the paper; Popykhova, E.B. — clinical data and performed laboratory investigations; Korshunovich, V.A. — collection of clinical data and creation and maintenance of the database.

Conflict of interest: The authors declare that they do not have any conflict of interests.

Source of funding: This study was carried out as part of the research project “Evaluating Neuroendocrine and Immune Relationships to Improve Reproductive Potential in Adolescents”, commissioned by the Russian Ministry of Health.


N.V. Bolotova (Corresponding author) — V.I. Razumovsky Saratov State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; 112 Bolshaya Kazachya St., Saratov, Russian Federation 410012. eLIBRARY.RU SPIN: 5061-1600. E-mail: kafedranv@mail.ru

S.V. Timofeeva — V.I. Razumovsky Saratov State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; 112 Bolshaya Kazachya St., Saratov, Russian Federation 410012. eLIBRARY.RU SPIN: 1342-1572. E-mail: kafedranv@mail.ru

V.K. Polyakov — V.I. Razumovsky Saratov State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; 112 Bolshaya Kazachya St., Saratov, Russian Federation 410012. eLIBRARY.RU SPIN: 9928-9682. E-mail: kafedranv@mail.ru

A.P. Averiyanov — V.I. Razumovsky Saratov State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; 112 Bolshaya Kazachya St., Saratov, Russian Federation 410012. eLIBRARY.RU SPIN: 1940-8093. E-mail: kafedranv@mail.ru

E.B. Popykhova — V.I. Razumovsky Saratov State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; 112 Bolshaya Kazachya St., Saratov, Russian Federation 410012. eLIBRARY.RU SPIN: 7810-3930. E-mail: kafedranv@mail.ru

V.A. Korshunovich — V.I. Razumovsky Saratov State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; 112 Bolshaya Kazachya St., Saratov, Russian Federation 410012. E-mail: kafedranv@mail.ru

Table 1
Hormonal parameters in study participants

t2_1.jpg

* The difference from the control group was statistically significant (р<0.05).

Note: Abbreviations in Tables 1 and 3: FSH = follicle-stimulating hormone, LH = luteinizing hormone, SSBG = sex steroid-binding globulin, TSH = thyroid-stimulating hormone.

Table 2
Menstrual function in study participants

t2_2.jpg

* The difference from the control group was statistically significant (р<0.05).

Table 3
Hormonal parameters in study participants before and after treatment (Groups 2 and 3)

t2_3.jpg

* The difference from parameters before treatment was statistically significant (р<0.05).

Received: 29.05.2019
Accepted: 15.07.2019

The Role of Kisspeptin in Menstrual Disorders in Adolescent Girls. Treatment of Clinically Manifested Endocrine Abnormalities
22 April 07:56
LITERATURE
  1. Borisenko M.Yu., Uvarova E.V., Batyrova Z.K. The clinical and pathogenic features of secondary amenorrhea in adolescent girls with normal blood gonadotropic hormone levels: an analytical review. Pediatric and Adolescent Reproductive Health. 2014; 3: 23–34. (in Russian)
  2. Borisenko M.Yu., Uvarova E.V. The current understanding of the etiology and pathogenesis of secondary amenorrhea in adolescent girls: an analytical review. Pediatric and Adolescent Reproductive Health. 2016; 4: 27–47. (in Russian)
  3. Kasyan V.N., Adamyan L.V. The pathophysiology of hot flashes. Neurohormonal regulation in focus. Reproductive Problems. 2017; 1: 115–21. (in Russian)
  4. Dedov I.I., Peterkova V.A., eds. Federal clinical guidelines (protocols) for management of children with endocrine pathology. M.: Praktika; 2014: 311–33. (in Russian)
  5. Nikitina I.L., Bairamov A.A., Khoduleva Yu.N., Shabanov P.D. The role of kisspeptins in normal and abnormal sexual development: new diagnostic and therapeutic options. Reviews of Clinical Pharmacology and Medication Therapy. 2014; 12(4): 3–12. (in Russian)
  6. Nikitina I.L. The timing of puberty: well-known and new issues. Arterial Hypertension. 2013; 19(3): 227–36. (in Russian). DOI: 10.18705/1607-419X-2013-19-3-227-236
  7. Pankov Yu.A. The role of kisspeptin and leptin in the regulation of fertility. Molecular Biology. 2015; 49(5): 707–15. (in Russian)
  8. Yarmolinskaya M.I., Ganbarli N.F., Aylamazyan E.K. Role of kisspeptine in regulation of reproductive function. Journal of Obstetrics and Women’s Diseases. 2016; 65(6): 4–18. (in Russian). DOI: 10.17816/JOWD6564-18
  9. Ganbarli N.F. The role of kisspeptin as an endogenous bioregulator in the pathogenesis of external genital endometriosis and the “classical phenotype” of polycystic ovary syndrome: a PhD thesis in Medicine. SPb.; 2018. 133 p. (in Russian)
  10. Chernukha G. Ye., Tabeeva G. I., Gusev D. V., Shmakov R. G. Kisspeptin and reproductive system. Doctor.Ru. 2017; 3(132): 73–78. (in Russian)
  11. Rhie Y.J. Kisspeptin/G protein coupled receptor-54 system as an essen­tial gatekeeper of pubertal development. Ann. Pediatr. Endocrinol. Metab. 2013; 18(2): 55–9. DOI: 10.6065/apem.2013.18.2.55
  12. Smith J.T. Sex steroid regulation of kisspeptin circuits. Adv. Exp. Med. Biol. 2013; 784: 275–95. DOI: 10.1007/978-1-4614-6199-9_13
  13. Apolihina I.A., Bolotova N.V., Raygorodskiy Yu.M., Timofeeva S.V., Basova T.A. Non-pharmacological regulation of the menstrual cycle in adolescent girls. Consilium Medicum. 2018; 20(6): 60–5. (in Russian). DOI: 10.26442/2075-1753_2018.6.60-65
  14. Bolotova N.V., Timofeeva S.V., Raygorodskiy Yu.M., Velikotskaya O.A., Paltseva Yu.V., Polyakov V.K. et al. Transcranial stimulation and magnetic therapy in treatment of adolescent girls with polycystic ovary syndrome. Pediatric and Adolescent Reproductive Health. 2018; 14(3): 22–33. (in Russian). DOI: 10.24411/1816-2134-2018-13002
  15. Salov I.A., Bolotova N.V., Labeznikova S.V., Chicheva G.V., Raigorodsky Yu.M. Transcranial physical methods in the treatment of reproductive system disorders in adolescent girls with obesity. Obstetrics and Gynecology. 2010; 5: 111–15. (in Russian)
  16. American Congress of Obstetricians and Gynecologists Committee Opinion. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. 2015. URL: https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Menstruation-in-Girls-and-Adolescents-Using-the-Menstrual-Cycle-as-a-Vital-Sign?IsMobileSet=false (дата обращения — 14.01.2020).
  17. Hu K.L., Zhao H., Chang H.M., Yu Y., Qiao J. Kisspeptin/kisspeptin receptor system in the ovary. Front. Endocrinol. (Lausanne). 2017; 8: 365. DOI: 10.3389/fendo.2017.00365
  18. Litvitsky P.F. Disorders of the endocrine system. The etiology and pathogenesis of endocrine diseases: adrenal gland dysfunction. Current Pediatrics. 2011; 10(5): 63–73. (in Russian)
  19. Adamyan L.V., Makiyan Z.N., Glybina T.M., Sibirskaya E.V., Ploshkina A.A. Issues in diagnosis and treatment of polycystic ovary syndrome in adolescent girls: an analytical review. Pediatric and Adolescent Reproductive Health. 2014; 3: 16–22. (in Russian)
  20. Gorbatenko N.V., Bezhenar V.F., Fishman M.B. The role of obesity in the development of reproductive disorders in women. Obesity and Metabolism. 2017; 14(1): 3–8. (in Russian). DOI: 10.14341/OMET201713-8
  21. Sergienko M.Yu., Yakovleva E.B., Mironenko D.M. The diagnosis and treatment of polycystic ovary syndrome in pediatric gynecology. International Journal of Endocrinology. 2015; 2(66): 59–60. (in Russian)
  22. Khashchenko E.P., Uvarova E.V., Mamedova F.Sh. Phenotypic features of polycystic ovary syndrome in adolescent girls. Pediatric and Adolescent Reproductive Health. 2017; 1: 37–50. (in Russian)
  23. Fauser B.C., Tarlatzis B.C., Rebar R.W., Legro R.S., Balen A.H., Lobo R. et al. Consensus on women's health aspect of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 2012; 97(1): 28–38.e25. DOI: 10.1016/j.fertnstert.2011.09.024
  24. Garkavi L.Kh., Kvakina E.B., Ukolova M.A. Adaptive reactions and body resistance. Rostov-on-Don; 1990. 126 p. (in Russian)
  25. Lebedev V.P., Sergienko V.I. An evidence-based approach to developing and validating the therapeutic effect of transcranial electrical stimulation of the brain’s protection mechanisms. In: Lebedev V.P., ed. Transcranial electrostimulation: experimental and clinical studies. Vol. 2. SPb.; 2005. 528 p. (in Russian)
  26. Ponomarenko G.N., Bolotova N.V., Raigorodsky Yu.M. Transcranial magnetic therapy. SPb.; 2016. 152 p. (in Russian)
Similar article
19 May 15:04, Allergology
V.M. Ganuzin, N.L. Chernaya, G.S. Maskova
Features of Specialised Medical Consultation of Adolescents with Bronchial Asthma: Clinical Observation
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)
19 May 14:30, Allergology
S.E. Mitskevich, I.A. Fedorov, A.I. Chuprynina, O.G. Rybakova
Use of Omalizumab in Management of Severe Uncontrolled Bronchial Asthma in Children
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)

Partners